Human medicines European public assessment report (EPAR): Mylotarg, gemtuzumab ozogamicin, Date of authorisation: 19/04/2018, Revision: 13, Status: Authorised

Submitted by Anonymous (not verified) on 16 October 2026 - 11:00

Human medicines European public assessment report (EPAR): Mylotarg, gemtuzumab ozogamicin, Date of authorisation: 19/04/2018, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Strimvelis, autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence, Date of authorisation: 26/05/2016, Revi

Submitted by Anonymous (not verified) on 16 October 2026 - 8:14

Human medicines European public assessment report (EPAR): Strimvelis, autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence, Date of authorisation: 26/05/2016, Revision: 13, Status: Authorised

Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines, Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 November 2026, 09:00 (CET) to 20 November 2026, 13:00 (CET)

Submitted by Anonymous (not verified) on 15 October 2026 - 16:28

Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines, Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 November 2026, 09:00 (CET) to 20 November 2026, 13:00 (CET)

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More